--- title: "Postmarket Cybersecurity Management | MedTech Cyber Tips" description: "Stay compliant and secure after your device is on the market. This guide outlines essential postmarket cybersecurity strategies for medical device…" lang: en json-ld: | [ { "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "@id": "https://medtechcybertips.com/#website", "url": "https://medtechcybertips.com/", "name": "MedTech Cyber Tips", "description": "The ultimate organized guide to medical device cybersecurity.", "inLanguage": "en-US", "publisher": { "@id": "https://medtechcybertips.com/#org" }, "potentialAction": { "@type": "SearchAction", "target": "https://medtechcybertips.com/topics?q={search_term_string}", "query-input": "required name=search_term_string" } }, { "@type": "Organization", "@id": "https://medtechcybertips.com/#org", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com/", "logo": "https://medtechcybertips.com/icon-512.png", "sponsor": { "@type": "Organization", "name": "Blue Goat Cyber", "url": "https://bluegoatcyber.com", "sameAs": [ "https://home.bluegoatcyber.com/", "https://codebluechart.com/", "https://why.bluegoatcyber.com/", "https://spdf.bluegoatcyber.com/", "https://threatmodel.bluegoatcyber.com/", "https://pentesting.bluegoatcyber.com/", "https://premarket.bluegoatcyber.com/", "https://fdaresponse.bluegoatcyber.com/", "https://postmarket.bluegoatcyber.com/", "https://goatwatch.bluegoatcyber.com/" ] } } ] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Postmarket Cybersecurity Management", "description": "This guide outlines essential postmarket cybersecurity strategies for medical device manufacturers to maintain FDA compliance, protect patient safety, and minimize business impact from emerging threats. It emphasizes continuous monitoring, proactive vulnerability management, and robust incident response planning to secure devices throughout their operational lifecycle.", "image": "https://medtechcybertips.com/og/topics/postmarket.png", "datePublished": "2025-01-01", "dateModified": "2026-08-18", "author": { "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team" }, "reviewedBy": { "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team" }, "publisher": { "@type": "Organization", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com", "sponsor": { "@type": "Organization", "name": "Blue Goat Cyber" } }, "mainEntityOfPage": "https://medtechcybertips.com/topics/postmarket", "about": "Postmarket" }, { "@context": "https://schema.org", "@type": "Person", "@id": "https://medtechcybertips.com/authors/editorial-team", "url": "https://medtechcybertips.com/authors/editorial-team", "name": "MedTech Cyber Tips Editorial Team", "jobTitle": "Medical Device Cybersecurity Editors", "description": "The MedTech Cyber Tips editorial team is a group of practitioners with hands-on experience across FDA premarket cybersecurity submissions, Secure Product Development Framework (SPDF) implementation, medical device threat modeling, and postmarket vulnerability management. Every article, checklist, and update on this site is reviewed for accuracy against the FDA's February 3, 2026 final premarket cybersecurity guidance, Section 524B of the FD&C Act, MDCG 2019-16 Rev.2, IEC 81001-5-1, ISO 14971, and the EU Cyber Resilience Act. The team also tracks 510(k) deficiency patterns and CVE trends affecting connected medical devices so guidance on the site stays current.", "knowsAbout": [ "Medical device cybersecurity", "FDA Section 524B", "FDA premarket cybersecurity guidance (Feb 3, 2026)", "Secure Product Development Framework", "SBOM and VEX", "Medical device threat modeling", "Postmarket vulnerability management", "EU MDR cybersecurity (MDCG 2019-16 Rev.2)", "EU Cyber Resilience Act", "IEC 81001-5-1", "ISO 14971 risk management" ], "sameAs": [ "https://bluegoatcyber.com/about" ], "worksFor": { "@type": "Organization", "name": "MedTech Cyber Tips", "url": "https://medtechcybertips.com/" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechcybertips.com" }, { "@type": "ListItem", "position": 2, "name": "Topics", "item": "https://medtechcybertips.com/topics" }, { "@type": "ListItem", "position": 3, "name": "Postmarket", "item": "https://medtechcybertips.com/topics/postmarket" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What are FDA postmarket cybersecurity expectations?", "acceptedAnswer": { "@type": "Answer", "text": "Manufacturers must monitor for new vulnerabilities affecting their devices (including third-party components in the SBOM), triage them against patient safety impact, remediate on defined timelines, and coordinate disclosure. Section 524B and the FDA's 2016 postmarket guidance define the framework." } }, { "@type": "Question", "name": "What is coordinated vulnerability disclosure (CVD)?", "acceptedAnswer": { "@type": "Answer", "text": "CVD is the published process by which security researchers can report vulnerabilities to you, receive acknowledgment, and coordinate on public disclosure once a fix is available. Every 'cyber device' manufacturer is expected to have and publish a CVD policy." } }, { "@type": "Question", "name": "How fast do we need to patch a critical vulnerability?", "acceptedAnswer": { "@type": "Answer", "text": "There is no bright-line statutory number. FDA expects timing to be justified by patient-safety risk, using an established framework such as CVSS or the ISPE Patch Framework. In practice, 30-90 days is typical for high-risk issues; anything longer needs explicit compensating controls." } }, { "@type": "Question", "name": "Do we have to notify customers about every vulnerability?", "acceptedAnswer": { "@type": "Answer", "text": "Notify customers when the vulnerability represents uncontrolled risk, when compensating controls are needed while a patch is developed, or when the fix requires customer action. Silent patching is not acceptable for issues that materially affect device security posture." } }, { "@type": "Question", "name": "Do we need CVEs for our own product vulnerabilities?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. FDA expects manufacturers to reserve and publish CVEs for vulnerabilities affecting their devices and to coordinate with CISA's ICS-MEDICAL advisory program where applicable. CVE issuance is essential for downstream hospital vulnerability tracking." } } ] } ] --- [Skip to main content](#main) [ MedTech Cyber Tips The Ultimate Guide ](/) [Home](/)[Find Your Path](/journey)[All Topics](/topics)Reference[About](/about) Search ⌘K [All topics](/topics) Postmarket # Postmarket Cybersecurity Management This guide outlines essential postmarket cybersecurity strategies for medical device manufacturers to maintain FDA compliance, protect patient safety, and minimize business impact from emerging threats. It emphasizes continuous monitoring, proactive vulnerability management, and robust incident response planning to secure devices throughout their operational lifecycle. For: Medical device manufacturers and cybersecurity professionals responsible for postmarket surveillance and vulnerability management. 7 min read Last updated Jul 10, 2026· 1mo ago Print Reviewed by [MedTech Cyber Tips Editorial Team](/authors/editorial-team) · Last reviewed July 2026 Postmarket vulnerability triage ### From CVE to defensible action Step 1 New CVE NVD / CISA KEV / researcher tip Step 2 SBOM match? Does any fielded device contain the component? Step 3 Assess VEX status Affected · Not affected · Fixed · Under investigation Step 4 Action CAPA · Advisory · Patch · No-op (with rationale) Every CVE deserves a recorded outcome - even "not affected" - to satisfy FDA postmarket expectations. 12 structured tips Checklist mode ## The walk-through 01 Technical ### Implement Continuous SBOM Monitoring Copy link Utilize automated tools to continuously track your Software Bill of Materials ([SBOM](/glossary/sbom)) for all devices. This helps detect vulnerabilities in third-party and open-source components as soon as they are identified, enabling proactive responses. 02 Technical ### Establish Real-Time Threat Monitoring & Alerts Copy link Set up systems to actively monitor cyber threats across your device ecosystem and receive instant notifications for CVEs affecting your devices. This allows for rapid mitigation before threats impact device functionality or patient safety. 03 Process ### Develop Robust Incident Response & Recovery Plans Copy link Create and regularly update proven incident response playbooks tailored for medical device patient-safety scenarios. These plans should minimize downtime, ensure audit-ready documentation, and protect both patients and your brand during a cybersecurity incident. 04 Technical ### Address Legacy Device Security Copy link Implement tailored risk mitigation strategies for older devices that may not be patchable. Focus on compensating controls to extend their lifecycle while balancing safety, functionality, and compliance. 05 Documentation ### Ensure FDA-Aligned Reporting & Evidence Copy link Generate audit-ready reports and exportable evidence that align with FDA postmarket guidance for all cybersecurity activities. This simplifies compliance and streamlines the audit process. 06 Technical ### Conduct Regular Security Testing Copy link Perform annual penetration testing and static application security testing (SAST) on your full device and ecosystem. This proactively identifies vulnerabilities and weaknesses before they can be exploited. 07 Process ### Integrate Patient-Safety Risk Triage Copy link Implement a process to assess each identified cybersecurity vulnerability within its clinical context, integrating [ISO 14971](/glossary/iso-14971) risk management principles. Prioritize remediation steps based on potential patient safety impact. 08 Technical ### Maintain a Centralized Vulnerability Tracking Portal Copy link Utilize a secure dashboard to track vulnerabilities, patches, and incidents in real-time. This provides full visibility and simplifies the management of your postmarket security posture. 09 Process ### Operate a PSIRT, Don't Just Publish a Policy Copy link A published [CVD](/glossary/cvd) policy without an operating Product Security Incident Response Team is a common deficiency. Document your [PSIRT](/glossary/psirt) cadence: intake triage SLA, severity rubric, coordination with CISA/ICS-CERT, and disclosure timeline. Keep a redacted example on file. 10 Documentation ### Master the VEX Justification Codes Copy link When marking a [CVE](/glossary/cve) 'not\_affected' in a [VEX](/glossary/vex) statement, use one of the five standard justifications: component\_not\_present, vulnerable\_code\_not\_present, vulnerable\_code\_not\_in\_execute\_path, vulnerable\_code\_cannot\_be\_controlled\_by\_adversary, or inline\_mitigations\_already\_exist. Free-text 'not applicable' is being flagged as unsupported. 11 Technical ### Monitor CISA's KEV Catalog Copy link Wire the CISA Known Exploited Vulnerabilities (KEV) catalog into your SBOM-monitoring pipeline. A KEV hit on any component in your device is a priority-one triage event regardless of [CVSS](/glossary/cvss) score. 12 Technical ### Diff Your SBOMs Between Releases Copy link Every release should produce an SBOM diff against the prior version. Reviewers increasingly ask what changed component-wise between submissions — a diffing workflow (syft + grype, or equivalent) makes this trivial and demonstrates operational maturity. ### Common pitfalls - Failing to continuously monitor Software Bill of Materials (SBOM) for emerging vulnerabilities. - Lack of real-time threat monitoring leading to delayed detection and response to cyberattacks. - Inadequate or untested incident response and recovery plans for medical device-specific scenarios. - Neglecting security updates and mitigation strategies for legacy medical devices. - Insufficient documentation and reporting that does not meet FDA postmarket guidance requirements. ### Your next steps 1. 1 Schedule a discovery session to assess current postmarket cybersecurity posture and challenges. 2. 2 Develop a comprehensive postmarket strategy, including SBOM monitoring, threat detection, and patch management. 3. 3 Implement continuous support and visibility solutions to ensure ongoing compliance and device security. ### Sources & references Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher. - FDA [Postmarket Management of Cybersecurity in Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices) - ISO/IEC [Coordinated Vulnerability Disclosure (ISO/IEC 29147 & 30111)](https://www.iso.org/standard/72311.html) - HSCC / NEMA [MDS2 - Manufacturer Disclosure Statement for Medical Device Security](https://healthsectorcouncil.org/mds2/) ## Frequently asked questions Quick answers to the questions teams most often ask about this topic. ### What are FDA postmarket cybersecurity expectations? Manufacturers must monitor for new vulnerabilities affecting their devices (including third-party components in the SBOM), triage them against patient safety impact, remediate on defined timelines, and coordinate disclosure. Section 524B and the FDA's 2016 postmarket guidance define the framework. ### What is coordinated vulnerability disclosure (CVD)? CVD is the published process by which security researchers can report vulnerabilities to you, receive acknowledgment, and coordinate on public disclosure once a fix is available. Every 'cyber device' manufacturer is expected to have and publish a CVD policy. ### How fast do we need to patch a critical vulnerability? There is no bright-line statutory number. FDA expects timing to be justified by patient-safety risk, using an established framework such as CVSS or the ISPE Patch Framework. In practice, 30-90 days is typical for high-risk issues; anything longer needs explicit compensating controls. ### Do we have to notify customers about every vulnerability? Notify customers when the vulnerability represents uncontrolled risk, when compensating controls are needed while a patch is developed, or when the fix requires customer action. Silent patching is not acceptable for issues that materially affect device security posture. ### Do we need CVEs for our own product vulnerabilities? Yes. FDA expects manufacturers to reserve and publish CVEs for vulnerabilities affecting their devices and to coordinate with CISA's ICS-MEDICAL advisory program where applicable. CVE issuance is essential for downstream hospital vulnerability tracking. Sponsored | how Blue Goat Cyber℠ helps ### Stay compliant after launch Blue Goat Cyber℠ runs postmarket vulnerability management, coordinated disclosure, and patch governance so your team can focus on the next release. [Set up postmarket cybersecurity](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) 4.9 / 5 · 15+ client reviews "Great results, would recommend." Michael Phillips 250+ FDA submissions · 0 rejections Veteran-owned, Scottsdale AZ Exclusively medical device cybersecurity On this page 7 min read - [01 · Implement Continuous SBOM Monitoring](#tip-0) - [02 · Establish Real-Time Threat Monitoring & Alerts](#tip-1) - [03 · Develop Robust Incident Response & Recovery Plans](#tip-2) - [04 · Address Legacy Device Security](#tip-3) - [05 · Ensure FDA-Aligned Reporting & Evidence](#tip-4) - [06 · Conduct Regular Security Testing](#tip-5) - [07 · Integrate Patient-Safety Risk Triage](#tip-6) - [08 · Maintain a Centralized Vulnerability Tracking Portal](#tip-7) - [09 · Operate a PSIRT, Don't Just Publish a Policy](#tip-8) - [10 · Master the VEX Justification Codes](#tip-9) - [11 · Monitor CISA's KEV Catalog](#tip-10) - [12 · Diff Your SBOMs Between Releases](#tip-11) - [Common pitfalls](#pitfalls) - [Your next steps](#next-steps) - [FAQ](#faq) Deep dive Hands-on help from Blue Goat Cyber The team behind this guide ships the work - read the canonical service page. [Visit on bluegoatcyber.com](https://bluegoatcyber.com/services/fda-postmarket-cybersecurity-services) Keep going ### Related topics [ Overview Start here. The big picture for MedTech security. Read guide ](/topics/home)[ Pentesting What's in scope (hardware, firmware, wireless, cloud, mobile), the methods reviewers expect, and how to read a pentest report against FDA cybersecurity guidance. Read guide ](/topics/pentesting)[ Monitoring Continuous vulnerability monitoring for fielded devices. Read guide ](/topics/goatwatch) Continue by phase Jump to all guides for the lifecycle phase that fits where you are. [Postmarket](/journey/postmarket) [All topics](/topics)[ Next in Postmarket Monitoring Continuous vulnerability monitoring for fielded devices. ](/topics/goatwatch) MedTech Cyber Tips The organized, end-to-end guide to medical device cybersecurity, from concept through postmarket. Part of the Blue Goat Cyber family. Topics - [Overview](/topics/home) - [Why It Matters](/topics/why) - [SPDF](/topics/spdf) - [Threat Modeling](/topics/threatmodel) - [Pentesting](/topics/pentesting) Reference - [Glossary](/glossary) - [FDA vs MDR](/compare) - [Resources](/resources) - [Updates](/updates) - [RSS feed](/rss.xml) © 2026 medtechcybertips.com. An educational resource sponsored by Blue Goat Cyber. Not legal or regulatory advice.